Literature DB >> 8452330

Biological basis for cancer treatment.

B A Chabner1.   

Abstract

The new knowledge of the regulation of cell growth and the genetic and biochemical changes that lead to malignancy have created many new opportunities for cancer drug discovery. These new targets include oncogenes, growth factors and their receptors, signal transduction pathways, and cell differentiation signals. Attempts to identify new therapies based on these targets can complement traditional drug discovery efforts that rely on high-volume screening of candidate natural products and synthetic chemicals against human tumor cell lines and against defined molecular reactions. Through modern computer-based data analysis, drug screening data can be used to establish mechanism of drug action of new agents; these analyses shed light on patterns of cross-resistance of new compounds and their interactions with defined molecular targets as well as allow selection of chemically and biologically unique agents as candidates for clinical development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452330     DOI: 10.7326/0003-4819-118-8-199304150-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

1.  Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes.

Authors:  Y Zhu; H A Gelbard; M Roshal; S Pursell; B D Jamieson; V Planelles
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  PQ1, a quinoline derivative, induces apoptosis in T47D breast cancer cells through activation of caspase-8 and caspase-9.

Authors:  Ying Ding; Thu Annelise Nguyen
Journal:  Apoptosis       Date:  2013-09       Impact factor: 4.677

4.  Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.

Authors:  K S Sridhar; A Krishan; T S Samy; R C Duncan; A Sauerteig; G V McPhee; M E Auguste; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas.

Authors:  Hyoun Wook Lee; Ki Hoon Song; Jin Woo Hong; Su Young Jeon; Dong Yeob Ko; Ki Ho Kim; Hyuk Chan Kwon; Suee Lee; Sung Hyun Kim; Dae Cheol Kim
Journal:  Korean J Pathol       Date:  2012-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.